News 
Market Data 
Discover
Replies to post #367501 on NorthWest Biotherapeutics Inc (NWBO)
Lykiri, I agree that is probably the chosen supplier, but I didn’t just pull that out of the air. The Flaskworks’ Agreement actually states this:
Quote:
(B) the initiation of EDEN system consumable sourcing from Saint Gobain or an equivalent supplier, via issued purchase order;
In recent years, cell-based therapies targeting the
immune system have emerged as promising strategies
for cancer treatment.
This review summarizes manufacturing challenges related to production of antigen presenting cells as a patient-tailored cancer therapy.
Understanding cell-material interactions is essential because in vitro cell culture manipulations to obtain mature antigen-producing cells can significantly alter their in vivo performance.
Traditional antigen producing cell culture protocols often rely on cell adhesion to surface-treated hydrophilic polystyrene flasks.
More recent commercial and investigational cancer immunotherapy products were manufactured using suspension cell culture in closed hydrophobic fluoropolymer bags.
The shift to closed cell culture systems can decrease risks of contamination by individual operators, as well as facilitate scale-up and automation.
Selecting closed cell culture bags over traditional open culture systems entails different handling procedures and processing controls, which can affect product quality.
Changes in culture vessels also entail changes in vessel materials and geometry, which may alter the cell microenvironment and resulting cell fate decisions.
Strategically designed culture systems will pave the way for the generation of more sophisticated and highly potent cell-based cancer vaccines.
As an increasing number of cell-based therapies enter the
clinic, the selection of appropriate cell culture vessels and
materials becomes a critical consideration that can impact the therapeutic efficacy of the product, and hence clinical outcomes and patient quality of life.
Several approaches are being investigated to achieve the full potential of DC-based vaccines, including increasing the
potency of the DCs, targeting the DCs to the tumors, and
inhibiting endogenous mechanisms that limit tumorspecific
immune responses
CONCLUSIONS
The combination of conventional treatments with novel
products such as cell-based therapeutics may augment
current strategies for patient healthcare.
Currently, a wide range of cell types, including hematopoietic stem cells, multipotent progenitors, and fully differentiated effector cells, is manufactured and tested for cell therapy applications.
The results of many recent clinical trials, however, remain ambivalent as to the efficacy and potency of these cell products.
Additive or synergistic effects between the administered cell products and existing drug-based therapies that lead to desirable clinical outcomes are being explored, but the mechanisms that may lead to these effects remain little understood.
Researchers have only recently started to explore the impact of changing cell culture “plastics” for clinical-scale production of cell therapy products.
Differences in mass transfer and mechanical and chemical properties can have drastic effects on cell fate.
Selecting the appropriate cell cultivation system is thus fundamental in the design and development of cell production strategies.
Although this review focused on studies in the immunotherapy field, other therapeutic cell types are being manufactured in the same or similar culture vessels.
The handling, processing, and material properties considerations presented in this review will impact the outcome of other therapeutic cell manufacturing processes.
Strategically designed cell culture systems will pave the way for the generation of potent cell-based cancer vaccines and other therapeutic cell types.
AI
